x32
Schrödinger Inc. announced 2013-1, the latest release of their entire suite of software programs, this covers tools for drug design, material science, biological modelling and general purpose modelling.
Scientific advances, significant usability improvements, and performance enhancements have been made to both the Small-Molecule Drug Discovery Suite and the Biologics Suite (featuring BioLuminate).
There are a huge number of new features and improvements in the small molecule drug discovery suite as well as Materials Science. However a couple of features caught my eye, pKa prediction for both rule-based and QM-based methods has been improved. Covalent ligand docking has been added and includes a variety of common docking chemistries. Improved pi-stacking interactions in docking. The molecular dynamics has been updated and now includes support for GPU-acceleration. The QM tools look to have been updated and the interface improved. ADME tools have been updated and in particular P450 site of metabolism has improved accuracy.
Predictive capabilities that can be applied across a wide range of chemical systems, including ,Reaction thermochemistry and reaction path exploration ,Rate constants for reactions and transport from transition state theory ,Validated models for calculating oxidation and reduction potentials, Accurate heats of formation and atomization energies for larger systems, Reliable properties for systems containing transition metals,Efficient calculation of electric field dependent properties,Prediction of vibrational and electronic spectra for complex systems,Multiple pre-defined calculation modes representing tested simulation parameters balancing speed and accuracy.
There has also been an update to PYMOL with improved rendering speeds and a couple of bug fixes.
New features in Schrödinger Software Release 2013: http://www.schrodinger.com/upload/files/LifeSciences_2013_NewFeatures_051513.pdf
About Schrödinger, L.L.C.
Schrödinger, L.L.C. is a scientific leader in computational drug design for pharmaceutical and biotechnology research. The company makes significant investments in R&D, which has led to major advances in the field of computational chemistry. Schrödinger has achieved breakthroughs in quantum chemistry, molecular modeling, force fields, molecular dynamics, protein structure determination, and docking. Schrödinger's methods development and applications papers have over one thousand citations and are among the most-cited scientific publications. The company's full product offerings range from general molecular modeling programs to a comprehensive suite of drug design software, including both ligand- and structure based methods. Schrödinger, L.L.C. is located at 101 SW Main Street, Suite 1300, Portland, OR 97204.
Name: Schrödinger Suite
Version: (32bit) 2013.1 Non Commercial
Home: www.schrodinger.com
Interface: english
OS: Windows XP / Vista / Seven
Download File Size:3.62 GB
|
